MedPath

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL

🇷🇴Romania
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

94

Active:19
Completed:24

Trial Phases

5 Phases

Phase 1:4
Phase 2:37
Phase 3:3
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (61 trials with phase data)• Click on a phase to view related trials

Phase 2
37 (60.7%)
Not Applicable
16 (26.2%)
Phase 1
4 (6.6%)
Phase 3
3 (4.9%)
Phase 4
1 (1.6%)

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Phase 3
Recruiting
Conditions
Acute Myeloid Leukemia
Relapse/Recurrence
Interventions
Drug: Low intensity therapies
Drug: High intensity therapies
First Posted Date
2024-12-03
Last Posted Date
2025-07-14
Lead Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Target Recruit Count
339
Registration Number
NCT06713837
Locations
🇷🇴

Fundeni Clinical Institute, Bucharest, Romania

🇨🇿

University Hospital Brno, Brno, Czechia

🇨🇿

University Hospital Hradec Králové, Hradec Králové, Czechia

and more 30 locations

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Phase 2
Recruiting
Conditions
Microsatellite Stable Colorectal Carcinoma
Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Interventions
Biological: Autologous Dendritic Cell (DC) Vaccine
First Posted Date
2024-07-26
Last Posted Date
2025-01-28
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
36
Registration Number
NCT06522919
Locations
🇮🇹

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l., Meldola, Forlì Cesena, Italy

🇮🇹

Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card.G.Panico", Tricase, Lecce, Italy

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
Conditions
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
First Posted Date
2024-06-14
Last Posted Date
2025-07-14
Lead Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Target Recruit Count
4000
Registration Number
NCT06459024
Locations
🇩🇪

University Hospital Aachen, Aachen, Germany

🇩🇪

University Hospital Greifswald, Greifswald, Germany

🇩🇪

University Hospital Halle, Halle, Germany

and more 28 locations

Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
Interventions
First Posted Date
2024-04-30
Last Posted Date
2025-02-03
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
18
Registration Number
NCT06390241
Locations
🇮🇹

IRCCS Istituto ROmagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l., Meldola, Forlì Cesena, Italy

National Database of Bone Metastases

Recruiting
Conditions
Bone Metastases
First Posted Date
2024-04-16
Last Posted Date
2024-04-16
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
800
Registration Number
NCT06367491
Locations
🇮🇹

A.U.S.L. Imola, Imola, Bologna, Italy

🇮🇹

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

🇮🇹

Osp. "Sacro Cuore di Gesù", Gallipoli, Lecce, Italy

and more 27 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 16
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath